BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 11767127)

  • 1. Serological tumor markers for monitoring breast cancer.
    Sölétormos G
    Dan Med Bull; 2001 Nov; 48(4):229-55. PubMed ID: 11767127
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients.
    Lauro S; Trasatti L; Bordin F; Lanzetta G; Bria E; Gelibter A; Reale MG; Vecchione A
    Anticancer Res; 1999; 19(4C):3511-5. PubMed ID: 10629644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study of four serological tumor markers for the detection of breast cancer.
    Clinton SR; Beason KL; Bryant S; Johnson JT; Jackson M; Wilson C; Holifield K; Vincent C; Hall M
    Biomed Sci Instrum; 2003; 39():408-14. PubMed ID: 12724928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An evaluation of CA 549, a circulating marker of breast cancer using a procedure for comparison with CA 15.3.
    Cazin JL; Gosselin P; Boniface B; Demaille MC; Demaille A
    Anticancer Res; 1992; 12(3):719-24. PubMed ID: 1622129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the BT-1 serum assay for breast cancer.
    Whitehurst MM; Aldenderfer PH; Sooy MM; Strelkauskas AJ
    Hum Antibodies; 1999; 9(3):155-60. PubMed ID: 10690628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tumor markers in breast cancer].
    Kurebayashi J
    Gan To Kagaku Ryoho; 2004 Nov; 31(12):2077-81. PubMed ID: 15570944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients.
    Kurebayashi J; Nomura T; Hirono M; Okubo S; Udagawa K; Shiiki S; Ikeda M; Nakashima K; Tanaka K; Sonoo H
    Jpn J Clin Oncol; 2006 Mar; 36(3):150-3. PubMed ID: 16520359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum tumor markers in patients with breast cancer.
    Lumachi F; Basso SM
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):921-31. PubMed ID: 15485325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tumor markers in metastatic breast carcinoma: correlations with clinical response].
    Winer Y; Martini MC; Pastorino G; Moraglio L; Vallauri M; Brondi P; Brema F
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):127-30. PubMed ID: 2092107
    [No Abstract]   [Full Text] [Related]  

  • 10. The early detection of disseminated (metastasized) breast cancer by serial tumour marker measurements.
    Jäger W
    Eur J Cancer Prev; 1993 Nov; 2 Suppl 3():133-9. PubMed ID: 8298443
    [No Abstract]   [Full Text] [Related]  

  • 11. First experiences with the use of CASA in mammary carcinoma.
    Weise J; Meisel M; Straube W
    Anticancer Res; 1997; 17(4B):3039-40. PubMed ID: 9329596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [BCA225].
    Kumamoto K; Kannagi R
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():669-71. PubMed ID: 16149607
    [No Abstract]   [Full Text] [Related]  

  • 13. Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma.
    Rodríguez CA; Cruz JJ; Martín T; Gómez A; Olaverri A; Hernández M
    Cancer; 2002 Aug; 95(3):670-1; author reply 671. PubMed ID: 12209762
    [No Abstract]   [Full Text] [Related]  

  • 14. Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients.
    Alix-Panabières C; Brouillet JP; Fabbro M; Yssel H; Rousset T; Maudelonde T; Choquet-Kastylevsky G; Vendrell JP
    J Immunol Methods; 2005 Apr; 299(1-2):177-88. PubMed ID: 15914200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor associated glycoprotein (TAG) 12: a new tumor marker in breast cancer.
    Heinze T; Lichtenegger W
    Anticancer Res; 2000; 20(6D):5049-52. PubMed ID: 11326666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pre- and post-therapeutic serum concentrations of mucin-like carcinoma-associated antigen in patients with breast cancer].
    Fuith LC; Artner-Dworzak E; Schröcksnadel H; Müller-Holzner E; Daxenbichler G; Heim K
    Gynakol Rundsch; 1989; 29 Suppl 2():397-9. PubMed ID: 2613061
    [No Abstract]   [Full Text] [Related]  

  • 17. The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients.
    Ławicki S; Szmitkowski M; Wojtukiewicz M
    Clin Chim Acta; 2006 Sep; 371(1-2):112-6. PubMed ID: 16631152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Serum markers in breast cancer and colorectal cancer (1997)].
    Bellet D; Mlika-Cabanne N; Bedenne L; Brun B; Demeaux JL; Legrand JL; Lorimier G; Mignotte H; Ollivier JM; Piperno-Neumann S; Rinaldi Y; Rousset H; Rymer JC; Laversin S
    Gynecol Obstet Fertil; 2001 Jan; 29(1):62-3. PubMed ID: 11217195
    [No Abstract]   [Full Text] [Related]  

  • 19. [Diagnostic value of combined detection of TPS, CA153 and CEA in breast cancer].
    Zheng H; Luo RC
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Oct; 25(10):1293-4, 1298. PubMed ID: 16234113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer markers during normal pregnancy.
    Botsis D; Sarandakou A; Kassanos D; Kontoravdis A; Rizos D; Protonotariou E; Phocas I; Creatsas G
    Anticancer Res; 1999; 19(4C):3539-41. PubMed ID: 10629649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.